We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

A phase 1 program including four separate studies was completed during the summer of 2021. Learn more about the clinical development of ROSgard.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Press releases
  • 03 Dec 2021  ·  Regulatory information

    Guard Therapeutics announces final result of rights issue

    Read more
  • 02 Dec 2021  ·  Regulatory information

    Guard Therapeutics announces preliminary result of rights issue

    Read more
  • 24 Nov 2021  ·  Regulatory information

    Guard Therapeutics publishes supplementary prospectus

    Read more
  • 22 Nov 2021  ·  Regulatory information

    Guard Therapeutics reports positive results from preclinical studies

    Read more
Show more
Calendar & reports
  • 22 Feb 2022

    Year-end report 2021

    Read more
  • 12 May 2022

    Annual General Meeting 2022 (including Annual Report 2021)

    Read more
  • 12 May 2022

    Interim report January-March 2022

    Read more
  • 23 Aug 2022

    Interim report April-June 2022

    Read more
Reports, presentations & in media
  • 31 May 2021 / Presentation

    Biostock

    Read more
  • 01 Feb 2021 / In media

    (in Swedish) Rutger Arnhults och EQT-veteranens läkemedelsbolag får tyskt klartecken

    Read more
  • 04 Jun 2020 / Analysis

    Monocl valuation report for cardiac surgery AKI 2018

    Read more
  • 04 Jun 2020 / Analysis

    Redeye valuation report 2019

    Read more
Show more